ProCE Banner Activity

Advances in Endometrial Cancer Therapy: Exploring the Role of Immunotherapy

Text Module

Gain expert guidance on emerging clinical data on the use of immune checkpoint inhibitor–based therapy in newly diagnosed and recurrent endometrial cancer.

This educational activity is intended for clinicians practicing medicine outside of the United States.

Released: December 22, 2020

Expiration: December 21, 2021

No longer available for credit.

Share

Faculty

Ana Oaknin

Ana Oaknin, MD, PhD

Head of Gynaecologic Cancer Programme
Department of Medical Oncology
Vall d’ Hebron University Hospital
Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain

Supporters

Supported by an educational grant from

GlaxoSmithKline

Target Audience

This program is intended for global gynecologic oncologists, medical oncologists, and other healthcare providers who care for patients with endometrial cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate current and emerging clinical trial data regarding new immunotherapy treatment options for patients with endometrial cancer
  • Identify current and emerging recommendations for molecular profiling in endometrial cancer and implications for prognosis and treatment decisions
  • Describe the role of immune checkpoint inhibitors in endometrial cancer classified as microsatellite stable
  • Discuss strategies to monitor and manage the unique adverse events associated with the emerging, novel treatment options for endometrial cancer

Faculty Disclosure

Primary Author

Ana Oaknin, MD, PhD

Head of Gynaecologic Cancer Programme
Department of Medical Oncology
Vall d’ Hebron University Hospital
Vall d’Hebron Institute of Oncology (VHIO)
Barcelona, Spain

Ana Oaknin, MD, PhD, has disclosed that she has received consulting fees from AstraZeneca, Clovis Oncology, Genmab, Immungen, PharmMar, Roche, and Tesaro.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Tanja Link, PhD

Editorial Contributor

Tanja Link, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy Quill, PhD, has no relevant conflicts of interest to report.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley has no relevant conflicts of interest to report.

Additional Information

Program Medium

This program has been made available online.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy.  PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

 

Goal


The goal of this activity is to improve global learners’ knowledge and competence in applying practice-changing clinical data and expert recommendations to incorporate recent data into the treatment of patients with endometrial cancer.